2. Search Result
Search Result
Results for "

cardioprotection

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

4

Peptides

6

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128090A
    Apstatin TFA

    		Aminopeptidase Cardiovascular Disease
    Apstatin TFA is a potent aminopeptidase P (APP) inhibitor with Ki values of 2.6, 0.64 µM for rat and human APP, respectively. Apstatin TFA shows cardioprotection .
    Apstatin TFA
  • HY-N0520
    Calycosin-7-O-β-D-glucoside
    3 Publications Verification

    Calycosin-7-glucoside

    		 Reactive Oxygen Species (ROS) Others
    Calycosin-7-O-β-D-glucoside is an isoflavone isolated from Astragali Radix. Calycosin-7-O-β-D-glucoside has variety of biological activities, such as neuroprotective, cardioprotection, anti-inflammation, and antioxidative stress effects .
    Calycosin-7-O-β-D-glucoside
  • HY-F0004
    Fosribnicotinamide
    Maximum Cited Publications
    19 Publications Verification

    β-Nicotinamide mononucleotide; β-NM; NMN

    		 Endogenous Metabolite Neurological Disease Cancer
    Fosribnicotinamide (β-nicotinamide mononucleotide) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD + intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
    Fosribnicotinamide
  • HY-103346
    MMPSI

    		Caspase Apoptosis Cardiovascular Disease
    MMPSI is a potent and selective small molecule caspase 3 and caspase 7 inhibitor with an IC50 of 1.7 μM for human caspase-3. MMPSI can significantly reduce ischemia-reperfusion-induced infarct size in the isolated rabbit heart, and reduce apoptosis in both the ischemic myocardium and isolated cardiomyocytes. MMPSI can be used for researching cardioprotection .
    MMPSI
  • HY-F0004R
    Fosribnicotinamide (Standard)

    β-Nicotinamide mononucleotide (Standard); β-NM (Standard); NMN (Standard)

    		 Reference Standards Endogenous Metabolite Neurological Disease Cancer
    Fosribnicotinamide (Standard) (β-Nicotinamide mononucleotide (Standard)) is the analytical standard of Fosribnicotinamide (HY-F0004 ). This product is intended for research and analytical applications. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD + intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
    Fosribnicotinamide (Standard)
  • HY-128090
    Apstatin

    		Aminopeptidase Cardiovascular Disease
    Apstatin is a potent aminopeptidase P (APP) inhibitor with Ki values of 2.6, 0.64 µM for rat and human APP, respectively. Apstatin shows cardioprotection .
    Apstatin
  • HY-106699
    Taprostene sodium

    CG 4203 sodium

    		 Prostaglandin Receptor nAChR Cardiovascular Disease
    Taprostene sodium is a partial agonist at prostanoid prostacyclin (IP) receptors. Taprostene sodium interacts additively with Prostaglandin E2 (PGE2) (HY-101952), ONO-AE1-259 (selective EP2 agonist), and acetylcholine. Taprostene sodium exerts a significant cardioprotection .
    Taprostene sodium
  • HY-19463A
    F15845

    		Sodium Channel Cardiovascular Disease
    F 15845 is a highly effective persistent sodium current blocker. F 15845 also is a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 can be used for the research of myocardium functional impairment .
    F15845
  • HY-N0520R
    Calycosin-7-O-β-D-glucoside (Standard)

    Calycosin-7-glucoside (Standard)

    		 Reference Standards Reactive Oxygen Species (ROS) Others
    Calycosin-7-O-β-D-glucoside (Standard) is the analytical standard of Calycosin-7-O-β-D-glucoside. This product is intended for research and analytical applications. Calycosin-7-O-β-D-glucoside is an isoflavone isolated from Astragali Radix. Calycosin-7-O-β-D-glucoside has variety of biological activities, such as neuroprotective, cardioprotection, anti-inflammation, and antioxidative stress effects .
    Calycosin-7-O-β-D-glucoside (Standard)
  • HY-176504
    Adenosine receptor agonist 2

    		Adenosine Receptor Cardiovascular Disease
    Adenosine receptor agonist 2 (Compound 10) is an adenosine A2B receptor (A2BR) agonist with an EC50 of 0.38 nM. Adenosine receptor agonist 2 significantly inhibits the accumulation of cAMP and calcium. Adenosine receptor agonist 2 can be used for cardioprotection research .
    Adenosine receptor agonist 2
  • HY-N0615
    Notoginsenoside R1
    2 Publications Verification

    Sanchinoside R1; Sanqi glucoside R1

    		 Amyloid-β Apoptosis Others
    Notoginsenoside R1 (Sanchinoside R1), a saponin, is isolated from P. notoginseng. Notoginsenoside R1 exhibits anti-oxidation, anti-inflammatory, anti-angiogenic, and anti-apoptosis activities. Notoginsenoside R1 provides cardioprotection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 also provides neuroprotection in H2O2-induced oxidative damage in PC12 cells .
    Notoginsenoside R1
  • HY-N0615R
    Notoginsenoside R1 (Standard)

    Sanchinoside R1 (Standard); Sanqi glucoside R1 (Standard)

    		 Reference Standards Amyloid-β Apoptosis Others
    Notoginsenoside R1 (Standard) is the analytical standard of Notoginsenoside R1. This product is intended for research and analytical applications. Notoginsenoside R1 (Sanchinoside R1), a saponin, is isolated from P. notoginseng. Notoginsenoside R1 exhibits anti-oxidation, anti-inflammatory, anti-angiogenic, and anti-apoptosis activities. Notoginsenoside R1 provides cardioprotection against ischemia/reperfusion (I/R) injury. Notoginsenoside R1 also provides neuroprotection in H2O2-induced oxidative damage in PC12 cells .
    Notoginsenoside R1 (Standard)
  • HY-153392
    TYA-018

    		Oxidative Phosphorylation HDAC Cardiovascular Disease
    TYA-018 is an orally active, potent and highly selective HDAC6 inhibitor. TYA-018 can protect heart function in mice. TYA-018 also enhances energetics in mice by increasing expression of targets associated with fatty acid metabolism, protein metabolism, and oxidative phosphorylation .
    TYA-018
  • HY-F0004S
    Fosribnicotinamide-d4

    β-Nicotinamide mononucleotide-d4; β-NM-d4; NMN-d4

    		 Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease Cancer
    Fosribnicotinamide-d4 (β-Nicotinamide mononucleotide-d4) is the deuterium labeled Fosribnicotinamide. Fosribnicotinamide is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
    Fosribnicotinamide-d4
  • HY-P3101
    GLP-1(28-36)amide

    		GCGR Cardiovascular Disease Metabolic Disease
    GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects .
    GLP-1(28-36)amide
  • HY-108573
    P-1075
    1 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    P-1075 is a potent activator of sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-KIR6), with an EC50 value of 45 nM for SUR2B-KIR6 channel activation . P-1075 also P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts .
    P-1075
  • HY-P3101A
    GLP-1(28-36)amide TFA

    		GCGR Cardiovascular Disease Metabolic Disease
    GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide TFA has anti-diabetic and cardioprotection effects .
    GLP-1(28-36)amide TFA
  • HY-105064R
    Zoniporide (Standard)

    CP-597396 (Standard)

    		 Reference Standards Na+/H+ Exchanger (NHE) Cardiovascular Disease
    Zoniporide (Standard) is the analytical standard of Zoniporide. This product is intended for research and analytical applications. Zoniporide (CP-597396) is a potent and selective NHE-1 inhibitor with cardioprotective activity. Zoniporide inhibits 22Na+ uptake by human NHE-1-expressing fibroblasts in a concentration-dependent manner (IC50=14 nM). Zoniporide inhibits platelet swelling in vitro with an IC50 of 0.059 μM. Zoniporide can be used in the study of cardiovascular disease .
    Zoniporide (Standard)
  • HY-105064
    Zoniporide
    1 Publications Verification

    CP-597396

    		 Na+/H+ Exchanger (NHE) Cardiovascular Disease
    Zoniporide (CP-597396) is a potent and selective NHE-1 inhibitor with cardioprotective activity. Zoniporide inhibits 22Na + uptake by human NHE-1-expressing fibroblasts in a concentration-dependent manner (IC50=14 nM). Zoniporide inhibits platelet swelling in vitro with an IC50 of 0.059 μM. Zoniporide can be used in the study of cardiovascular disease .
    Zoniporide
  • HY-76201
    Dexrazoxane hydrochloride
    10+ Cited Publications

    ICRF-187 hydrochloride; ADR-529 hydrochloride; NSC-169780 hydrochloride

    		 Others Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Dexrazoxane hydrochloride (ICRF-187 hydrochloride) is a heart protectant that can help preserve ovarian function and fertility. Dexrazoxane hydrochloride has antioxidant and anti-inflammatory properties, can cross the blood-brain barrier, improves motor function disorders, and offers neuroprotective effects, making it useful in the study of neurodegenerative diseases .
    Dexrazoxane hydrochloride
  • HY-121586
    Nafazatrom

    Bay g 6575

    		 Lipoxygenase Cardiovascular Disease
    Nafazatrom (Bay g 6575) is an orally active cardioprotective agent that protects against ischemic damage. Nafazatrom dose-dependently inhibits neutrophil aggregation, superoxide anion generation, arachidonic acid metabolism, and to a lesser extent the release of β-glucosidase, platelet aggregation or arachidonic acid in vitro. Acid metabolism has no significant effect. In a dog ischemia-reperfusion model, Nafazatrom (10 mg/kg; po) reduced infarct size and the occurrence of arrhythmias and rescued ischemic myocardial function without affecting any hemodynamic changes. The basis of Nafazatrom's cardioprotection may be inhibition of neutrophil function and cellular infiltration in vitro .
    Nafazatrom
  • HY-108573R
    P-1075 (Standard)

    		Potassium Channel Cardiovascular Disease
    P-1075 (Standard) is the analytical standard of P-1075. This product is intended for research and analytical applications. P-1075 is a potent activator of sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-KIR6), with an EC50 value of 45 nM for SUR2B-KIR6 channel activation . P-1075 also P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts .
    P-1075 (Standard)
  • HY-105064B
    Zoniporide hydrochloride

    CP-597396 hydrochloride

    		 Na+/H+ Exchanger (NHE) Cardiovascular Disease
    Zoniporide (CP-597396) hydrochloride is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride inhibits human NHE-1 (IC50=14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC50=59 nM) .
    Zoniporide hydrochloride
  • HY-105064DR
    Zoniporide hydrochloride hydrate (Standard)

    CP-597396 hydrochloride hydrate (Standard)

    		 Reference Standards Na+/H+ Exchanger (NHE) Cardiovascular Disease
    Zoniporide (hydrochloride hydrate) (Standard) is the analytical standard of Zoniporide (hydrochloride hydrate). This product is intended for research and analytical applications. Zoniporide (CP-597396) hydrochloride hydrate is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride hydrate inhibits human NHE-1 (IC50=14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride hydrate potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC50=59 nM) .
    Zoniporide hydrochloride hydrate (Standard)
  • HY-105064D
    Zoniporide hydrochloride hydrate
    1 Publications Verification

    CP-597396 hydrochloride hydrate

    		 Na+/H+ Exchanger (NHE) Cardiovascular Disease
    Zoniporide (CP-597396) hydrochloride hydrate is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride hydrate inhibits human NHE-1 (IC50=14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride hydrate potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC50=59 nM) .
    Zoniporide hydrochloride hydrate
  • HY-135746
    OR-1896
    2 Publications Verification

    		 Potassium Channel Phosphodiesterase (PDE) Drug Metabolite Apoptosis Cardiovascular Disease
    OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K + channels and has Ca 2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation .
    OR-1896
  • HY-135746R
    OR-1896 (Standard)

    		Reference Standards Potassium Channel Phosphodiesterase (PDE) Drug Metabolite Apoptosis Cardiovascular Disease
    7-epi-Taxol (Standard) is the analytical standard of 7-epi-Taxol. This product is intended for research and analytical applications. 7-epi-Taxol is an active metabolite of taxol, with activity comparable to that of taxol against cell replication, promoting microtubule bundle formation and against microtubule depolymerization.
    OR-1896 (Standard)
  • HY-19310
    AMP-579

    		Adenosine Receptor Cardiovascular Disease Metabolic Disease
    AMP-579 is an adenosine receptor agonist that primarily targets adenosine A1 and A2A receptors (with Ki values of 1.7 and 4.5 nM for the A1 receptor in rat brain and adipocytes, and a Ki value of 56 nM for the A2A receptor in rat brain). AMP-579 inhibits lipolysis, restores insulin-dependent glucose transport, and reduces heart rate through the activation of A1 receptors, while it induces vasodilation, particularly in coronary arteries, through the activation of A2A receptors (with an IC50 of 0.3 μM in porcine coronary arterial rings). AMP 579 shows potential for application in cardioprotection and the treatment of acute myocardial infarction .
    AMP-579
  • HY-14993
    SCH79797
    3 Publications Verification

    		 Protease Activated Receptor (PAR) Apoptosis Cardiovascular Disease
    SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .
    SCH79797
  • HY-14993R
    SCH79797 (Standard)

    		Protease Activated Receptor (PAR) Apoptosis Cardiovascular Disease
    SCH79797 (Standard) is the analytical standard of SCH79797. This product is intended for research and analytical applications. SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .
    SCH79797 (Standard)
  • HY-14994R
    SCH79797 dihydrochloride (Standard)

    		Protease Activated Receptor (PAR) Apoptosis Cardiovascular Disease
    SCH79797 (dihydrochloride) (Standard) is the analytical standard of SCH79797 (dihydrochloride). This product is intended for research and analytical applications. SCH79797 dihydrochloride is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .
    SCH79797 dihydrochloride (Standard)
  • HY-14994
    SCH79797 dihydrochloride
    3 Publications Verification

    		 Protease Activated Receptor (PAR) Apoptosis Cardiovascular Disease
    SCH79797 dihydrochloride is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 dihydrochloride inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 dihydrochloride inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 dihydrochloride has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 dihydrochloride also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes .
    SCH79797 dihydrochloride
  • HY-P1723
    Spexin
    1 Publications Verification

    Neuropeptide Q

    		 Neuropeptide Y Receptor Apoptosis Ferroptosis Autophagy Cardiovascular Disease Neurological Disease
    Spexin (Neuropeptide Q) is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin can function through both central and peripheral actions. Spexin upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
    Spexin
  • HY-P1723A
    Spexin TFA

    Neuropeptide Q TFA

    		 Neuropeptide Y Receptor Apoptosis Ferroptosis Autophagy Cardiovascular Disease Metabolic Disease
    Spexin (Neuropeptide Q) TFA is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin TFA can function through both central and peripheral actions. Spexin TFA upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin TFA improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin TFA can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
    Spexin TFA
  • HY-117970
    MMPI-1154

    		MMP Cardiovascular Disease
    MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) MMP-2 inhibitor(IC50=6.6 μM) and can be used for the study of acute myocardial infarction. MMPI-1154 also inhibits the activity of MMP-13, MMP-1 and MMP-9 with IC50s of 1.8 μM,10 μM, and 13 μM, respectively .
    MMPI-1154

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: